Precision oncology continues to challenge the “one-size-fits-all” dogma. Under the precision
oncology banner, cancer patients are screened for molecular tumor alterations that predict …

Improving the effectiveness of preclinical predictions of human drug responses is critical to
reducing costly failures in clinical trials. Recent advances in cell biology, microfabrication …

Cancer is one of the leading causes of human death, despite enormous efforts to explore
cancer biology and develop anticancer therapies. The main challenges in cancer research …

Highlights•Traditional drug screening model systems are inadequate.•Organoid-on-a-chip
platforms stand to significantly advance drug and toxicology screening.•A wide variety or …

Drug evaluation has always been an important area of research in the pharmaceutical
industry. However, animal welfare protection and other shortcomings of traditional drug …

Despite the progress achieved in nanomedicine during the last decade, the translation of
new nanotechnology‐based therapeutic systems into clinical applications has been slow …

Novel microfluidic tools allow new ways to manufacture and test drug delivery systems.
Organ-on-a-chip systems—microscale recapitulations of complex organ functions—promise …

The exact mechanistic understanding of cancer metastasis continues to be unknown,
although it is a major cause of death worldwide. Along with the tumor mass, the tumor …

Tumor progression, including metastasis, is significantly influenced by factors in the tumor
microenvironment (TME) such as mechanical force, shear stress, chemotaxis, and hypoxia …

Microfluidic lumen-based systems are microscale models that recapitulate the anatomy and
physiology of tubular organs. These technologies can mimic human pathophysiology and …